2 completed, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
Follow CHEK2 Gene Mutation: new trials by email Literature Review of CHEK2 Gene Mutation trials Research Report on CHEK2 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer Exemestane, Tamoxifen - Breast Cancer, Ductal Carcinoma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 140 | 2026-09-09 | 2026-03-30 |
| Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations Androgen Deprivation Therapy (ADT), Niraparib/Abiraterone Acetate DAT, Abiraterone Acetate - Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation | Phase 2 | Withdrawn | Qian Qin | 2025-10-01 | 2026-04-08 | |
| Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion Tamoxifen 10 mg Tablet, Intermittent caloric restriction, Step counter Device - BRCA Mutation, PALB2 Gene Mutation | Phase 2 | Completed | European Institute of Oncology | 110 | 2024-06-21 | 2026-09-11 |
| Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy - ATM Gene Mutation, BRCA1 Gene Mutation | Phase 2 | Terminated | University of California, Davis | 11 | 2020-02-25 | 2026-05-14 |
| Olaparib In Metastatic Breast Cancer Olaparib - Metastatic Breast Cancer, Invasive Breast Cancer | Phase 2 | Active not recruiting | Beth Israel Deaconess Medical Center | 114 | 2018-04-01 | 2026-01-05 |
| Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - ATM Gene Mutation, ATR Gene Mutation | Phase 2 | Completed | SWOG Cancer Research Network | 51 | 2017-03-03 | 2021-06-23 |
Breast Neoplasms (2) · Breast Carcinoma In Situ (1) · Carcinoma, Ductal (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Fanconi Anemia, Complementation Group D1 (1) · Prostatic Neoplasms (1)
Neoplasms (4) · Neoplasms by Site (4) · Breast Diseases (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Adenocarcinoma (2) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Ductal, Lobular, and Medullary (2) · Neoplasms, Glandular and Epithelial (2) · Breast Neoplasms (1) · Carcinoma in Situ (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1)
Tamoxifen (2) · niraparib (2) · Abiraterone Acetate (1) · Androgen Antagonists (1) · Docetaxel (1) · Prednisone (1) · Tablets (1) · exemestane (1) · olaparib (1) · talazoparib (1)
Beth Israel Deaconess Medical Center (1) · Dana-Farber Cancer Institute (1) · European Institute of Oncology (1) · Qian Qin (1) · SWOG Cancer Research Network (1) · University of California, Davis (1)
United States (4) · Canada (1) · Italy (1)
Bernardo Bonanni, MD (1) · Judy Garber, MD. MPH (1) · Marc Dall'Era (1) · Nadine Tung, MD (1) · Qian Qin, MD (1) · Vassiliki Papadimitrakopoulou (1)
PMID 33119476, PMID 36710203, PMID 39226292, PMID 41604601
2023 (1), P30CA093373 (1), U10CA180888 (1)